DE1617483A1 - Arzneimittel zur Behandlung der organischen und funktionellen Nachtblindheit - Google Patents
Arzneimittel zur Behandlung der organischen und funktionellen NachtblindheitInfo
- Publication number
- DE1617483A1 DE1617483A1 DE19671617483 DE1617483A DE1617483A1 DE 1617483 A1 DE1617483 A1 DE 1617483A1 DE 19671617483 DE19671617483 DE 19671617483 DE 1617483 A DE1617483 A DE 1617483A DE 1617483 A1 DE1617483 A1 DE 1617483A1
- Authority
- DE
- Germany
- Prior art keywords
- night blindness
- photonic
- adapter
- medicament according
- organic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000001140 Night Blindness Diseases 0.000 title claims description 15
- 239000003814 drug Substances 0.000 title claims description 12
- 229940079593 drug Drugs 0.000 title claims description 4
- 230000000694 effects Effects 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 230000005855 radiation Effects 0.000 claims description 5
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 4
- 208000001491 myopia Diseases 0.000 claims description 4
- 230000004379 myopia Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 208000003464 asthenopia Diseases 0.000 claims description 3
- 229930003944 flavone Natural products 0.000 claims description 3
- 150000002213 flavones Chemical class 0.000 claims description 3
- 235000011949 flavones Nutrition 0.000 claims description 3
- 150000007965 phenolic acids Chemical class 0.000 claims description 3
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims description 2
- 229930002877 anthocyanin Natural products 0.000 claims description 2
- 235000010208 anthocyanin Nutrition 0.000 claims description 2
- 239000004410 anthocyanin Substances 0.000 claims description 2
- 150000004636 anthocyanins Chemical class 0.000 claims description 2
- 239000007857 degradation product Substances 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 125000004072 flavinyl group Chemical group 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 150000002596 lactones Chemical class 0.000 claims description 2
- 125000003367 polycyclic group Chemical group 0.000 claims description 2
- 230000004242 retinal defects Effects 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 201000004569 Blindness Diseases 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000002571 electroretinography Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000009048 phenolic acids Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- JMSVCTWVEWCHDZ-UHFFFAOYSA-N syringic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1O JMSVCTWVEWCHDZ-UHFFFAOYSA-N 0.000 description 2
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 229930192627 Naphthoquinone Natural products 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000004313 glare Effects 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 229960004068 hexachlorophene Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- -1 lactoflavins Chemical compound 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002791 naphthoquinones Chemical class 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- YIBXWXOYFGZLRU-UHFFFAOYSA-N syringic aldehyde Natural products CC12CCC(C3(CCC(=O)C(C)(C)C3CC=3)C)C=3C1(C)CCC2C1COC(C)(C)C(O)C(O)C1 YIBXWXOYFGZLRU-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR91872A FR6716M (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1967-01-20 | 1967-01-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1617483A1 true DE1617483A1 (de) | 1972-02-17 |
Family
ID=8624142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19671617483 Pending DE1617483A1 (de) | 1967-01-20 | 1967-12-20 | Arzneimittel zur Behandlung der organischen und funktionellen Nachtblindheit |
Country Status (4)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012019295A1 (en) * | 2010-08-13 | 2012-02-16 | Tony Antakly | Bioactive compounds in camel urine and milk |
-
1967
- 1967-01-20 FR FR91872A patent/FR6716M/fr not_active Expired
- 1967-12-14 GB GB56832/67A patent/GB1200928A/en not_active Expired
- 1967-12-20 DE DE19671617483 patent/DE1617483A1/de active Pending
-
1968
- 1968-01-19 BE BE709665D patent/BE709665A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB1200928A (en) | 1970-08-05 |
| FR6716M (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1969-02-17 |
| BE709665A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1968-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69224080T2 (de) | Verwendung von nsaid zur behandlung von demenz | |
| DE3338995C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE69532469T2 (de) | Adhäsion inhibierender Vaccinium Extrakt | |
| DE69130705T2 (de) | Antivirale zusammensetzungen und verfahren zu ihrer anwendung | |
| EP0313942A1 (de) | Verwendung von Fluoronderivaten und Mittel zur Kontrastierung von bösartigen Neubildungen bei deren Diagnostik | |
| DE69937574T2 (de) | Verwendung des pharmazeutischen präparates "histochrome" zur behandlung des akuten herzinfarkts und ischämischer herzerkrankungen | |
| EP2496269B1 (en) | Quantifying cell death | |
| DE1617483A1 (de) | Arzneimittel zur Behandlung der organischen und funktionellen Nachtblindheit | |
| Resnick et al. | Accentuation of the psychological effects of LSD-25 in normal subjects treated with reserpine | |
| DE3818022C2 (de) | Weichgelatinekapsel | |
| EP1001756A1 (de) | Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe | |
| EP2996675B1 (de) | Pharmazeutische formulierung, verfahren zur herstellung der pharmazeutischen formulierung und infusionslösung sowie deren verwendung als medizinprodukt und/oder als medikament | |
| EP2282751B1 (de) | Kompartimentspezifische pflanzenextraktkombination aus ginkgo biloba- und ginseng-extrakt mit tandemwirkung | |
| DE60303131T2 (de) | Synergistische wechselwirkung von abacavir und alovudin | |
| DE3780702T2 (de) | Verwendung von etodolac zur senkung des blutgehalts an harnsaeure. | |
| DE317509C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE2015877A1 (de) | Arzneimittel | |
| CH644374A5 (en) | Water-soluble hydroxyflavone ethers and medicaments containing them | |
| DE3136455A1 (de) | "verwendung von caerulein oder dessen pharmazeutisch vertraeglichen salzen bei der bekaempfung vo psychotischen krankheitszustaenden" | |
| DE660842C (de) | Verfahren zur Herstellung peroral wirksamer Pankreashormonpraeparate | |
| DE2551962C3 (de) | Verwendung eines Extraktes aus verschiedenen Spezies von Helleborus | |
| DE3546505C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE2949707C2 (de) | Parenteral applizierbare wäßrige Arzneimittellösungen von Diphenylmethylpiperazin-Derivaten | |
| DE4206375A1 (de) | Arzneimittel zur behandlung von morbus alzheimer | |
| DE2105024C (de) | Schlafmittel |